A CASE OF MULTIPLE LUNG METASTASES OF RENAL CELL CARCINOMA FAILING TO RESPOND TO INTERFERON-α (IFN-α) AND SUNITINIB BUT MARKEDLY RESPONDING TO EVEROLIMUS

DOI Web Site PubMed 29 References

Bibliographic Information

Other Title
  • インターフェロンαおよびスニチニブによる治療にて進行後，エベロリムスの投与にて部分奏効となった腎細胞癌術後肺転移の1例
  • 症例報告 インターフェロンαおよびスニチニブによる治療にて進行後,エベロリムスの投与にて部分奏効となった腎細胞癌術後肺転移の1例
  • ショウレイ ホウコク インターフェロンa オヨビ スニチニブ ニ ヨル チリョウ ニテ シンコウ ゴ,エベロリムス ノ トウヨ ニテ ブブン ソウコウ ト ナッタ ジンサイボウガン ジュツゴ ハイ テンイ ノ 1レイ

Search this article

Abstract

The case pertains to a 47-year-old male. He consulted our institute regarding a tumor in his right kidney. Endoscopic retroperitoneal nephrectomy of the right kidney was conducted to remove the tumor. The postoperative pathology was Renal Cell Carcinoma (Clear cell carcinoma, pT1b, pNx, V (+), Fuhrman grade 4). Multiple lung metastases were observed upon CT scan the following year. Sunitinib was administered following Interferon α (IFN-α) therapy; however, the lung metastases became larger, so administration of everolimus at 10 mg/day was commenced. The lung metastatic lesion became smaller upon CT scan from 6 weeks following administration, and it was determined that the therapeutic effect was PR. The PR was still maintained upon CT scan 31 weeks following administration but the lung metastatic lesion still remained; therefore, right lower lobe resection and lymph node biopsy were conducted upon obtaining informed consent. The administration of everolimus at 10 mg/day is still subsequently being continued due to viable tumor cells being observed in the lung metastatic lesion and the lymph node. At present, 43 weeks have past since the start of everolimus administration, but no new metastatic lesions have been observed.

Journal

References(29)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top